GRM3
GRM3 (Metabotropic glutamate receptor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Chromophobe renal cell carcinoma and 2 more.
Overview
G protein-coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signalling inhibits adenylate cyclase activity.
IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Chromophobe Renal Cell Carcinoma, Oesophageal Adenocarcinoma, Melanoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · GRM3 (Metabotropic glutamate receptor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Chromophobe renal cell carcinoma and 2 more.
- 1 · What it is
GRM3 (Metabotropic glutamate receptor 3) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Renal cell carcinoma, Oesophageal cancer, Chromophobe renal cell carcinoma and 2 more.
- 2 · What goes wrong in cancer
G protein-coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors.
- 3 · How drugs use it
No product in this corpus aims at GRM3 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:4595 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q14832 (protein name, function text, keywords and locations (REST API)); IntOGen GRM3 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
G protein-coupled receptor for glutamate. Ligand binding causes a conformation change that triggers signalling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signalling inhibits adenylate cyclase activity. Location: Cell membrane (UniProt). Locus 7q21.11-q21.12 (HGNC).
- Renal cell carcinoma: IntOGen driver in 1 cohort (CHRCC)
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Chromophobe renal cell carcinoma: IntOGen driver in 1 cohort (CHRCC)
- Oesophageal and junctional adenocarcinoma: IntOGen driver in 1 cohort (ESCA)
- Melanoma: IntOGen driver in 1 cohort (MEL)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"GRM3" OR ABSTRACT:"GRM3" OR TITLE:"glutamate metabotropic receptor 3" OR ABSTRACT:"glutamate metabotropic receptor 3" OR TITLE:"Metabotropic glutamate receptor 3" OR ABSTRACT:"Metabotropic glutamate receptor 3" OR TITLE:"GPRC1C" OR ABSTRACT:"GPRC1C" OR TITLE:"mGlu3" OR ABSTRACT:"mGlu3" OR TITLE:"MGLUR3" OR ABSTRACT:"MGLUR3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about GRM3, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCANT1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetZNF208
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetCTNND2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Melanoma.
- TargetNUMA1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetZNF750
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen.
- TargetNUTM1
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Melanoma.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, IntOGen, Melanoma.
- TargetMSN
Shares Oesophageal and junctional adenocarcinoma, Renal cell carcinoma, Oesophageal cancer, IntOGen.